Research & Development
Our mission at uniQure is to deliver curative gene therapies that transform the lives of patients. We have an ongoing clinical program in hemophilia B and preclinical proof-of-concept for a gene therapy in Huntington's disease.
News & Events
uniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B.
Click here to view press release.
uniQure is always on the look-out for talent and highly motivated and skilled people who want to make a difference. From technical level positions up to management, uniQure has a lot to offer.